Ragifilimab
Ragifilimab (INCAGN-1876) is an agonist monoclonal antibody targeting the glucocorticoid-induced TNFR-related protein (GITR) . Ragifilimab binds to and activates GITR on T cells, which stimulates the immune system to enhance its anti-tumor activity. Ragifilimab can be used for advanced or metastatic solid tumors research[1].
Product Specifications
CAS Number
2207590-51-8
Product Name Alternative
INCAGN-1876
UNSPSC
12352203
Target
TNF Receptor
Type
Inhibitory Antibodies
Related Pathways
Apoptosis
Applications
Cancer-programmed cell death
Field of Research
Cancer; Inflammation/Immunology
Assay Protocol
https://www.medchemexpress.com/ragifilimab.html
Purity
99.32
Solubility
H2O
Smiles
[Ragifilimab]
Molecular Weight
(146.46 kDa)
References & Citations
[1]Hernandez-Guerrero T, et al: Not Ready for Prime Time. Clin Cancer Res. 2022 Sep 15;28 (18) :3905-3907.
Shipping Conditions
Dry Ice
Storage Conditions
Store at -80°C for 2 years
Scientific Category
Inhibitory Antibodies
Clinical Information
No Development Reported
Isoform
TNFRSF18/GITR/CD357
Available Sizes
Frequently Asked Questions
Explore Other Products
Browse additional items from our catalog
CD32 (Fc Gamma RIIa) (FCGR2A/479), CF647 conjugate, 0.1mg/mL
